Sirtuin modulators control reactive gliosis in an in vitro model of alzheimer's disease

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Scuderi, Caterina ^a   Stecca, Claudia ^a   Bronzuoli R , Maria ^a   Rotili, Dante ^a   Valente, Sergio ^a   Mai, Antonello ^a   Steardo, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

AGK 2, sirtuins; Alzheimer's disease; Astrocyte; Beta amyloid; Reactive gliosis; Resveratrol

Indexed keywords

AGK 2; AMYLOID BETA PROTEIN[1-42]; CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROLASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN S100B; RESVERATROL; SIRTUIN 1; SIRTUIN 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME REGULATION; GLIOSIS; IN VITRO STUDY; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; REACTIVE GLIOSIS; WESTERN BLOTTING;

EID: 84904631078     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00089     Document Type: Article

References (46)

1. Allaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A., et al. (2010). Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J. Neurosci. 30, 3326-3338. doi: 10.1523/JNEUROSCI.5098-09.2010
2. Alzheimer's Association Report. (2013). 2013 Alzheimer's disease facts and figures. Alzheimers and Dement. 9, 208-245. doi: 10.1016/j.jalz.2013.02.003
3. Anekonda, T. S. (2006). Resveratrol-a boon for treating Alzheimer's disease? Brain Res. Rev. 52, 316-326. doi: 10.1016/j.brainresrev.2006.04.004
4. Block, M. L., and Hong, J. S. (2005). Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77-98. doi: 10.1016/j.pneurobio.2005.06.004
5. Caricasole, A., Copani. A., Caruso, A., Caraci, F., Iacovelli, L., Sortino, M. A., et al. (2003). The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol. Sci. 24, 233-238. doi: 10.1016/S0165-6147(03)00100-7
6. Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L. F., Kwon, H., Yi, S., et al. (2005). SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem. 280, 40364-40374. doi: 10.1074/jbc.M509329200
7. Craft, J. M., Watterson, D. M., and Van Eldik, L. J. (2006). Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 53, 484-490. doi: 10.1002/glia.20306
8. de Oliveira, R. M., Pais, T. F., and Outeiro, T. F. (2010). Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug Targets 11, 1270-1280. doi: 10.2174/1389450111007011270
9. Di Filippo, M., Sarchielli, P., Picconi, B., and Calabresi, P. (2008). Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol. Sci. 29, 402-412. doi: 10.1016/j.tips.2008.06.005
10. Donato, R., and Heizmann, C. W. (2010). S100B protein in the nervous system and cardiovascular apparatus in normal and pathological conditions. Cardiovasc. Psychiatry Neurol. 2010, 929712. doi: 10.1155/2010/929712
11. Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J., et al. (2013). Functions of S100 proteins. Curr. Mol. Med. 13, 24-57. doi: 10.2174/156652413804486214
12. Ferreira, S. T., Clarke, J. R., Bomfim, T. R., and De Felice, F. G. (2014). Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement. 10, S76-S83. doi: 10.1016/j.jalz.2013.12.010
13. Gan, L., and Mucke, L. (2008). Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58, 10-14. doi: 10.1016/j.neuron.2008.03.015
14. Griffin, W. S. (2006). Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 83, 470S-474S. doi: 10.1111/j.1365-2567.2009.03225.x
15. Haigis, M. C., and Sinclair, D. A. (2010). Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295. doi: 10.1146/annurev.pathol.4.110807.092250
16. Harting, K., and Knöll, B. (2010). SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. Eur. J. Cell Biol. 89, 262-269. doi: 10.1016/j.ejcb.2009.11.006
17. Hoppe, J. B., Rattray, M., Tu, H., Salbego, C. G., and Cimarosti, H. (2013). SUMO-1 conjugation blocks beta-amyloid-induced astrocyte reactivity. Neurosci. Lett. 546, 51-56. doi: 10.1016/j.neulet.2013.04.050
18. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196. doi: 10.1038/nature01960
19. Jefremov, V., Zilmer, M., Zilmer, K., Bogdanovic, N., and Karelson, E. (2007). Antioxidative effects of plant polyphenols: from protection of G protein signaling to prevention of age-related pathologies. Ann. N. Y. Acad. Sci. 1095, 449-457. doi: 10.1196/annals.1397.048
20. Julien, C., Tremblay, C., Emond, V., Lebbadi, M., Salem, N. Jr., Bennett, D. A., et al. (2009). Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 68, 48-58. doi: 10.1097/NEN.0b013e3181922348
21. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., et al. (2007). SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179. doi: 10.1038/sj.emboj.7601758
22. Li, Y., Yokota, T., Gama, V., Yoshida, T., Gomez, J. A., Ishikawa, K., et al. (2007). Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 14, 2058-2067. doi: 10.1038/sj.cdd.4402219
23. Lu, T., Pan, Y., Kao, S. Y., Li, C., Kohane, I., Chan, J., et al. (2004). Gene regulation and DNA damage in the ageing human brain. Nature 429, 883-891. doi: 10.1038/nature02661
24. Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., et al. (2010). SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 107, 7927-7932. doi: 10.1073/pnas.1002924107
25. Meda, L., Baron, P., and Scarlato, G. (2001). Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging 22, 885-893. doi: 10.1016/S0197-4580(01)00307-4
26. Menard, C., Bastianetto, S., and Quirion, R. (2013). Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front. Cell. Neurosci. 7:281. doi: 10.3389/fncel.2013.00281
27. Michan, S., and Sinclair, D. (2007). Sirtuins in mammals: insights into their biological function. Biochem. J. 404, 1-13. doi: 10.1042/BJ20070140
28. Mrak, R. E., and Griffin, W. S. (2001). The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 22, 915-922. doi: 10.1016/S0197-4580(01)00293-7
29. O'Callaghan, J. P., and Sriram, K. (2005). Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf. 4, 433-442. doi: 10.1517/14740338.4.3.433
30. Olabarria, M., Noristani, H. N., Verkhratsky, A., and Rodríguez, J. J. (2010). Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 58, 831-838. doi: 10.1002/glia.20967
31. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufarev, I., Strathearn, K. E., Amore, A. M., et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519. doi: 10.1126/science.1143780
32. Outeiro, T. F., Marques, O., and Kazantsev, A. (2008). Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta 1782, 363-369. doi: 10.1016/j.bbadis. 2008.02.010
33. Qin, W., Chachich, M., Lane, M., Roth, G., Bryant, M., de Cabo, R., et al. (2006a). Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis. 10, 417-422.
34. Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., et al. (2006b). Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745-21754. doi: 10.1074/jbc.M602909200
35. Repetto, G., del Peso, A., and Zurita, J. L. (2008). Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 3, 1125-1131. doi: 10.1038/nprot.2008.75
36. Scuderi, C., Esposito, G., Blasio, A., Valenza, M., Arietti, P., Steardo, L. Jr., et al. (2011). Palmitoylethanolamide counteracts reactive astrogliosis induced by ß-amyloid peptide. J. Cell. Mol. Med. 15, 2664-2674. doi: 10.1111/j.1582-4934.2011.01267.x
37. Scuderi, C., and Steardo, L. (2013). Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 12, 62-69. doi: 10.2174/1871527311312010011
38. Scuderi, C., Stecca, C., Iacomino, A., and Steardo, L. (2013). Role of astrocytes in major neurological disorders: the evidence and implications. IUBMB Life 65, 957-961. doi: 10.1002/iub.1223
39. Scuderi, C., Valenza, M., Stecca, C., Esposito, G., Carratù, M. R., and Steardo, L. (2012). Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-a. J. Neuroinflammation 9, 49. doi: 10.1186/1742-2094-9-21
40. Spires-Jones, T. L., Fox, L. M., Rozkalne, A., Pitstick, R., Carlson, G. A., and Kazantsev, A. G. (2012). Inhibition of sirtuin 2 with sulfobenzoic acid derivative AK1 is non-toxic and potentially neuroprotective in a mouse model of frontotemporal dementia. Front. Pharmacol. 3:42. doi: 10.3389/fphar.2012.00042
41. Sun, A. Y., Wang, Q., Simonyi, A., and Sun, G. Y. (2010). Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 41, 375-383. doi: 10.1007/s12035-010-8111-y
42. Tang, B. L., and Chua, C. E. (2008). SIRT1 and neuronal diseases. Mol. Aspects Med. 29, 187-200. doi: 10.1016/j.mam.2007.02.001
43. Tuppo, E. E., and Arias, H. R. (2005). The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37, 289-305. doi: 10.1016/j.biocel.2004.07.009
44. Vairano, M., Dello Russo, C., Pozzoli, G., Battaglia, A., Scambia, G., Tringali, G., et al. (2002). Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur. J. Neurosci. 16, 584-592. doi: 10.1046/j.1460-9568.2002.02125.x
45. Verkhratsky, A., and Butt, A. M. (2007). Glial Neurobiology. Chichester: John Wiley and Sons Ltd. doi: 10.1002/9780470517796
46. Wyss-Coray, T., and Rogers, J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2:a006346. doi: 10.1101/cshperspect.a006346